Abstract 1634P
Background
Molecular profiling is increasingly implemented to guide treatment of pancreatic ductal adenocarcinoma (PDAC), especially if enrolment in clinical trials is considered. The aim of our study was to describe actionable alterations detected in KRAS mutant (KRASm) versus KRAS wild-type (KRASwt) PDAC, as the latter is considered as harboring more molecular alterations.
Methods
This monocentric prospective study included patients with locally advanced or metastatic PDAC who underwent next-generation sequencing (NGS) on liquid biopsy and/or tissue sample between 2015 and 2022 (FoundationOne® CDx, Liquid CDx or Oncomine Comprehensive Assay), as part of the BIP study (NCT02534649).
Results
233 patients with a PDAC underwent NGS: 63 on tissue samples alone, 95 on liquid biopsies alone, and 75 on both tissue and liquid. Among 170 liquid biopsies, 90 were informative (52.9%). Among 196 patients with informative NGS, 172 patients (87.8%) had a KRASm PDAC, and 24 a KRASwt PDAC (12.2%). Median overall survival (OS) in the KRASwt group was 27.8 versus 20.3 months for KRASm patients (HR 0.58, CI (0.39-0.87), p=0.02). ESCAT alterations were found in 17.3% of total population, 25.0% in KRASwt group and 16.3% in KRASm group. All 7 BRCA1/2 germline mutations were detected in the KRASm group. 1 NTRK fusion was found in a KRASwt PDAC. BRCA1/2 somatic mutations, PIK3CA hotspot mutations, MDM2 amplifications and ERRB2 alterations were found similarly in both groups. We detected 5 KRAS G12C mutations. Patients harboring ESCAT alterations had a median OS of 25.0 versus 19.6 months for those without (HR 0.85, 95%CI (0.58 – 1.23), p=0.40). 66 patients (33.7%) were eligible to early-phase trials according to the molecular tumor board and 10 patients (5.1%) were effectively enrolled, with a range of time to progression between 22 days and 11 months.
Conclusions
Although actionable mutations are more prevalent in the KRASwt group, 16.3% of KRASm patients harbored ESCAT alterations, underlying the need for molecular profiling regardless of KRAS status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Italiano: Financial Interests, Personal, Advisory Board: Bayer, Roche, Philips, Chugai, GSK; Financial Interests, Institutional, Coordinating PI: Bayer, AstraZeneca, Roche, MSD, Ipsen, Merck. L. Blouin: Financial Interests, Personal, Other: AstraZeneca. S. Cousin: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, BMS, Novartis, AbbVie; Financial Interests, Personal, Principal Investigator: MSD, BMS, Sanofi, AbbVie, Roche. S. Pernot: Financial Interests, Personal, Invited Speaker: Bayer, Amgen, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Servier, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22